HDAC1-mediated CDK1 decrotonylation inhibits colorectal cancer proliferation by regulating cell cycle and apoptosis
Frontiers in Oncology · 16.06.2026 · 16
DOI: 10.3389/fonc.2026.1759160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 16.06.2026. Verfasst von Dongling Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Central laboratory of Chongqing Emergency Medical Center, Chongqing University Central Hospital; School of Medicine, Chongqing University, Chongqing,…. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) represents the third most prevalent malignancy globally and ranks as the second leading contributor to cancer-related mortality. Lysine crotonylation, a novel post-translational modification, regulates chromatin dynamics through its dual substrate specificity targeting both histones and non-histone proteins.
Methods
We quantitatively compared crotonylation levels between colorectal tumor specimens and paired adjacent normal tissues. The function and mechanism of specific crotonylation sites in hypercrotonylated proteins were further explored both in vitro and in vivo by introducing mutations that mimic decrotonylation at the crotonylation sites of CDK1.
Results
Quantitative analysis revealed a significant elevation of global crotonylation in colorectal tumor specimens compared to adjacent normal tissues. Through LC-MS/MS analysis, we identified the CDK1 9th lysine crotonylated, and that decrotonylated of CDK1-K9 inhibited colorectal tumor proliferation and migration in vitro and in vivo by arresting the cell cycle at the G2/M phase and inducing apoptosis. Mechanistically, histone acetyltransferase hMOF (KAT8) and histone deacetylase HDAC1 co-mediated CDK1 K9 crotonylation, and the decrotonylated mutation was observed to decrease the interaction of CDK1 with cyclin and kinase activity. Moreover, CDK1 K9 decrotonylation and CDK1 inhibitor RO-3306 exert synergistic effects.
Conclusion
We revealed the role of non-histone protein crotonylation in regulating the proliferation and migration of colorectal tumor. Crotonylation inhibited cell proliferation through the crotonylated CDK1 K9 by arresting the cell cycle and inducing apoptosis, and exerts a synergistic effect with the RO-3306 inhibitor.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Central laboratory of Chongqing Emergency Medical Center, Chongqing University Central Hospital; School of Medicine, Chongqing University, Chongqing, China.
- College of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
- Center Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
- Department of Cardiology, Chongqing Medical Emergency Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, China.
Förderung
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Li, D., Cai, Q., Lin, L., Li, L., Chen, Y., Feng, T., Zhou, X., Xie, J., Fu, X., Li, C., Xiao, J., & Yang, F. (2026). HDAC1-mediated CDK1 decrotonylation inhibits colorectal cancer proliferation by regulating cell cycle and apoptosis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1759160
Vancouver
Li D, Cai Q, Lin L, Li L, Chen Y, Feng T, et al. HDAC1-mediated CDK1 decrotonylation inhibits colorectal cancer proliferation by regulating cell cycle and apoptosis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1759160
BibTeX
@article{Li2026,
author = {Li, Dongling and Cai, Qinrui and Lin, Ling and Li, Li and Chen, Yao and Feng, Tianlin and Zhou, Xiaoya and Xie, Jia and Fu, Xiaohong and Li, Chuanwei and Xiao, Jun and Yang, Fan},
title = {HDAC1-mediated CDK1 decrotonylation inhibits colorectal cancer proliferation by regulating cell cycle and apoptosis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1759160}
}
EUVIMED